Molecular mechanisms of necrosis in glioblastoma: The role of glutamate excitotoxicity

Cancer Biology and Therapy

Volumn 8, Issue 19, 2009, Pages 1791-1797

  Noch, Evan ^a   Khalili, Kamel ^a  

^a TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Glioblastoma; Glutamate uptake; Necrosis; NF B; Tumor necrosis factor alpha

Indexed keywords

ADENOSINE TRIPHOSPHATE; CALCIUM ION; EXCITATORY AMINO ACID TRANSPORTER 2; GLUTAMIC ACID; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IONOTROPIC RECEPTOR; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; TUMOR NECROSIS FACTOR ALPHA;

ASTROCYTE ELEVATED GENE 1; CALCIUM CELL LEVEL; CANCER SURVIVAL; EXCITOTOXICITY; GENE; GLIOBLASTOMA; HUMAN; PREDICTOR VARIABLE; PROGNOSIS; REVIEW; SIGNAL TRANSDUCTION; SURVIVAL TIME; TUMOR NECROSIS;

EID: 73549104022     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.8.19.9762     Document Type: Review

References (69)

1. Central Brain Tumor Registry of the United States: Statistical Report: Primary Brain Tumors in the United States, 1998-2002. Hinsdale IL, Central Brain Tumor Registry of the United States 2006; www.cbtrus.org.
2. Okamoto Y, Di Patre PL, Burkhard C, Horstman S, Jourde B, Fahey M, et al. Population-based study on incidence, survival rates and genetic alterations of low-grade diffuse astrocytomas and oligodendrogliomas. Acta Neuropathol 2004; 108:49-56.
3. Schröck E, Blume C, Meffert MC, du Manoir S, Bershc W, Kiessling M, et al. Recurrent gain of chromosome arm 7q in low-grade astrocytic tumors studied by comparative genomic hybridization. Genes Chromosomes Cancer 1996; 15:199-205.
4. Reifenberger G, Louis DN. Oligodendroglioma: toward molecular definitions in diagnostic neurooncology. J Neuropathol Exp Neurol 2003; 62:111-26.
5. Maintz D, Fiedler K, Koopmann J, Rollbrocker B, Nechev S, Lenartz D, et al. Molecular genetic evidence for subtypes of oligoastrocytomas. J Neuropathol Exp Neurol 1997; 56:1098-104.
6. Louis DN. Molecular pathology of malignant gliomas. Annu Rev Pathol 2006; 1:97-117.
7. Barker FG 2nd, Davis RL, Chang SM, Prados MD. Necrosis as a prognostic factor in glioblastoma multiforme. Cancer 1996; 77:1161-6.
8. Homma T, Fukushima T, Vaccarella S, Yonekawa Y, Di Patre PL, Franceschi S. Correlation among pathology, genotype and patient outcomes in glioblastoma. J Neuropathol Exp Neurol 2006; 65:846-54.
9. Miller CR, Dunham CP, Scheithauer BW, Perry A. Significance of necrosis in grading of oligodendroglial neoplasms: a clinicopathologic and genetic study of newly diagnosed high-grade gliomas. J Clin Oncol 2006; 24:5419-26.
10. Pierallini A, Bonamini M, Pantano P, Palmeggiani F, Raguso M, Osti MF, et al. Radiological assessment of necrosis in glioblastoma: variability and prognostic value. Neuroradiology 1998; 40:150-3.
11. Smith SF, Simpson JM, Brewer JA, Sekhon LH, Biggs MT, Cook RJ, Little NS. The presence of necrosis and/or microvascular proliferation does not influence survival of patients with anaplastic oligodendroglial tumours: review of 98 patients. J Neurooncol 2006; 80:75-82.
12. Padanilam BJ. Cell death induced by acute renal injury: a perspective on the contributions of apoptosis and necrosis. Am J Physiol Renal Physiol 2003; 284:608-27.
13. Lipton SA, Rosenberg PA. Excitatory amino acids as a final common pathway for neurologic disorders. N Engl J Med 1994; 330:613-22.
14. Nicholls D, Attwell D. The release and uptake of excitatory amino acids. Trends Pharmacol Sci 1990; 11:462-8.
15. McCarley RW, Faux SF, Shenton ME, Nestor PG, Adams J. Event-related potentials in schizophrenia: their biological and clinical correlates and a new model of schizophrenic pathophysiology. Schizophr Res 1991; 4:209-31.
16. Rothstein JD. Current hypotheses for the underlying biology of amyotrophic lateral sclerosis. Ann Neurol 2009; 65:3-9.
17. Ludolph AC, Meyer T, Riepe MW. The role of excitotoxicity in ALS - what is the evidence? J Neurol 2000; 247:7-16.
18. Sontheimer H. A role for glutamate in growth and invasion of primary brain tumors. J Neurochem 2008; 105:287-95.
19. Danbolt NC. Glutamate uptake. Prog Neurobiol 2001; 65:1-105.
20. Ye ZC, Rothstein JD, Sontheimer H. Compromised glutamate transport in human glioma cells: reduction-mislocalization of sodium-dependent glutamate transporters and enhanced activity of cystine-glutamate exchange. J Neurosci 1999; 19:10767-77.
21. Rijpkema M, Schuuring J, van der Meulen Y, van der Graaf M, Bernsen H, Boerman R, et al. Characterization of oligodendrogliomas using short echo time 1H MR spectroscopic imaging. NMR Biomed 2003; 16:12-8.
22. Roslin M, Henriksson R, Bergström P, Ungerstedt U, Bergenheim AT. Baseline levels of glucose metabolites, glutamate and glycerol in malignant glioma assessed by stereotactic microdialysis. J Neurooncol 2003; 61:151-60.
23. Biber K, Neumann H, Inoue K, Boddeke HW. Neuronal 'On' and 'Off ' signals control microglia. Trends Neurosci 2007; 30:596-602.
24. Chu K, Lee ST, Sinn DI, Ko SY, Kim EH, Kim JM, et al. Pharmacological induction of ischemic tolerance by glutamate transporter-1 (EAAT2) Upregulation. Stroke 2007; 38:177-82.
25. Münch C, Penndorf A, Schwalenstöcker B, Troost D, Ludolph AC, Ince P, et al. Impaired RNA splicing of 5'-regulatory sequences of the astroglial glutamate transporter EAAT2 in human astrocytoma. J Neurol Neurosurg Psychiatry 2001; 71:675-8.
26. Tan S, Wood M, Maher P. Oxidative stress induces a form of programmed cell death with characteristics of both apoptosis and necrosis in neuronal cells. J Neurochem 1998; 71:95-105.
27. Choi DW. Calcium and excitotoxic neuronal injury. Ann N Y Acad Sci 1994; 747:162-71.
28. Cho Y, Bannai S. Uptake of glutamate and cysteine in C-6 glioma cells and in cultured astrocytes. J Neurochem 1990; 55:2091-7.
29. Proskuryakov SY, Konoplyannikov AG, Gabai VL. Necrosis: a specific form of programmed cell death? Exp Cell Res 2003; 283:1-16.
30. Boston-Howes W, Gibb SL, Williams EO, Pasinelli P, Brown RH Jr, Trotti D. Caspase-3 cleaves and inactivates the glutamate transporter EAAT2. J Biol Chem 2006; 281:14076-84.
31. Mabrouk GM, Ali EM, El-Rehany MA, El-Samoly HM. TGFbeta1, TNFalpha and cytochrome c in human astrocytic tumors: a short-term follow up and correlation with survival. Clin Biochem 2007; 40:255-60.
32. Roessler K, Suchanek G, Breitschopf H, Kitz K, Matula C, Lassmann H, et al. Detection of tumor necrosis factor-alpha protein and messenger RNA in human glial brain tumors: comparison of immunohistochemistry with in situ hybridization using molecular probes. J Neurosurg 1995; 83:291-7.
33. Raza SM, Fuller GN, Rhee CH, Huang S, Hess K, Zhang W, Sawaya R. Identification of necrosis-associated genes in glioblastoma by cDNA microarray analysis. Clin Cancer Res 2004; 10:212-21.
34. Raza SM, Lang FF, Aggarwal BB, Fuller GN, Wildrick DM, Sawaya R. Necrosis and glioblastoma: a friend or a foe? A review and a hypothesis. Neurosurgery 2002; 51:2-12.
35. Fine SM, Angel RA, Perry SW, Epstein LG, Rothstein JD, Dewhurst S, et al. Tumor necrosis factor alpha inhibits glutamate uptake by primary human astrocytes. Implications for pathogenesis of HIV-1 dementia. J Biol Chem 1996; 271:15303-6.
36. Szymocha R, Akaoka H, Dutuit M, Malcus C, Didier-Bazes M, Belin MF, et al. Human T-cell lymphotropic virus type 1-infected T lymphocytes impair catabolism and uptake of glutamate by astrocytes via Tax-1 and tumor necrosis factor alpha. J Virol 2000; 74:6433-41.
37. Zou JY, Crews FT. TNFalpha potentiates glutamate neurotoxicity by inhibiting glutamate uptake in organotypic brain slice cultures: neuroprotection by NFkappaB inhibition. Brain Res 2005; 1034:11-24.
38. Chao CC, Hu S. Tumor necrosis factor-alpha potentiates glutamate neurotoxicity in human fetal brain cell cultures. Dev Neurosci 1994; 16:172-9.
39. Huang TL, O'Banion MK. Interleukin-1beta and tumor necrosis factor-alpha suppress dexamethasone induction of glutamine synthetase in primary mouse astrocytes. J Neurochem 1998; 71:1436-42.
40. Gelbard HA, Dzenko KA, DiLoreto D, del Cerro C, del Cerro M, Epstein LG. Neurotoxic effects of tumor necrosis factor alpha in primary human neuronal cultures are mediated by activation of the glutamate AMPA receptor subtype: implications for AIDS neuropathogenesis. Dev Neurosci 1993; 15:417-22.
41. Carmen J, Rothstein JD, Kerr DA. Tumor necrosis factor-alpha modulates glutamate transport in the CNS and is a critical determinant of outcome from viral encephalomyelitis. Brain Res 2009; 1263:143-54.
42. Su ZZ, Leszczyniecka M, Kang DC, Sarkar D, Chao W, Volsky DJ, et al. Insights into glutamate transport regulation in human astrocytes: cloning of the promoter for excitatory amino acid transporter 2 (EAAT2). Proc Natl Acad Sci USA 2003; 100:1955-60.
43. Ida T, Hara M, Nakamura Y, Kozaki S, Tsunoda S, Ihara H. Cytokine-induced enhancement of calcium-dependent glutamate release from astrocytes mediated by nitric oxide. Neurosci Lett 2008; 432:232-6.
44. Hsu L, Rockenstein E, Mallory M, Hashimoto M, Masliah E. Altered expression of glutamate transporters under hypoxic conditions in vitro. J Neurosci Res 2001; 64:193-202.
45. Ohashi M, Amano S, Hazama F, Handa J. Hypoxic effects on glutamate uptake in cultured glial cells. Acta Pathol Jpn 1993; 43:154-9.
46. Boycott HE, Wilkinson JA, Boyle JP, Pearson HA, Peers C. Differential involvement of TNFalpha in hypoxic suppression of astrocyte glutamate transporters. Glia 2008; 56:998-1004.
47. Kang DC, Su ZZ, Sarkar D, Emdad L, Volsky DJ, et al. Cloning and characterization of HIV-1-inducible astrocyte elevated gene-1, AEG-1. Gene 2005; 353:8-15.
48. Emdad L, Sarkar D, Su ZZ, Randolph A, Boukerche H, Valerie K, Fisher PB. Activation of the nuclear factor kappaB pathway by astrocyte elevated gene-1: implications for tumor progression and metastasis. Cancer Res 2006; 66:1509-16.
49. Lee SG, Su ZZ, Emdad L, Sarkar D, Fisher PB. Astrocyte elevated gene-1 (AEG-1) is a target gene of oncogenic Ha-ras requiring phosphatidylinositol 3-kinase and c-Myc. Proc Natl Acad Sci USA 2006; 103:17390-5.
50. Lee SG, Su ZZ, Emdad L, Sarkar D, Franke TF, Fisher PB. Astrocyte elevated gene-1 activates cell survival pathways through PI3K-Akt signaling. Oncogene 2008; 27:1114-21.
51. Sarkar D, Park ES, Emdad L, Lee SG, Su ZZ, Fisher PB. Molecular basis of nuclear factor-kappaB activation by astrocyte elevated gene-1. Cancer Res 2008; 68:1478-84.
52. Angileri FF, Aguennouz M, Conti A, La Torre D, Cardali S, Crupi R, et al. Nuclear factor-kappaB activation and differential expression of survivin and Bcl-2 in human grade 2-4 astrocytomas. Cancer 2008; 112:2258-66.
53. Zschocke J, Allritz C, Engele J, Rein T. DNA methylation dependent silencing of the human glutamate transporter EAAT2 gene in glial cells. Glia 2007; 55:663-74.
54. Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang SI, et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast and prostate cancer. Science 1997; 275:1943-7.
55. Ali IU, Schriml LM, Dean M. Mutational spectra of PTEN/MMAC1 gene: a tumor suppressor with lipid phosphatase activity. J Natl Cancer Inst 1999; 91:1922-32.
56. Kwon CH, Zhao D, Chen J, Alcantara S, Li Y, Burns DK, et al. Pten haploinsufficiency accelerates formation of high-grade astrocytomas. Cancer Res 2008; 68:3286-94.
57. Kleihues P, Ohgaki H. Primary and secondary glioblastomas: from concept to clinical diagnosis. Neuro Oncol 1999; 1:44-51.
58. Ohgaki H, Kleihues P. Genetic pathways to primary and secondary glioblastoma. Am J Pathol 2007; 170:1445-53.
59. Koul D, Takada Y, Shen R, Aggarwal BB, Yung WK. PTEN enhances TNF-induced apoptosis through modulation of nuclear factor-kappaB signaling pathway in human glioma cells. Biochem Biophys Res Commun 2006; 350:463-71.
60. Haas-Kogan D, Shalev N, Wong M, Mills G, Yount G, Stokoe D. Protein kinaseB (PKB/Akt) activity is elevated in glioblastoma cells due to mutation of the tumor suppressor PTEN/MMAC. Curr Biol 1998; 8:1195-8.
61. Sonoda Y, Ozawa T, Aldape KD, Deen DF, Berger MS, Pieper RO. Akt pathway activation converts anaplastic astrocytoma to glioblastoma multiforme in a human astrocyte model of glioma. Cancer Res 2001; 61:6674-8.
62. Morales M, González-Mejía ME, Bernabé A, Hernández-Kelly LC, Ortega A. Glutamate activates protein kinaseB (PKB/Akt) through AMPA receptors in cultured Bergmann glia cells. Neurochem Res 2006; 31:423-9.
63. 2+-permeable AMPA receptors regulate growth of human glioblastoma via Akt activation. J Neurosci 2007; 27:7987-8001.
64. Perkinton MS, Ip JK, Wood GL, Crossthwaite AJ, Williams RJ. Phosphatidylinositol 3-kinase is a central mediator of NMDA receptor signalling to MAP kinase (Erk1/2), Akt/PKB and CREB in striatal neurones. J Neurochem 2002; 80:239-54.
65. Portera-Cailliau C, Price DL, Martin LJ. Non-NMDA and NMDA receptor-mediated excitotoxic neuronal deaths in adult brain are morphologically distinct: Further evidence for an apoptosis-necrosis continuum. J Comp Neurol 1997; 378:88-104.
66. Chalecka-Franaszek E, Chuang DM. Lithium activates the serine/threonine kinase Akt-1 and suppresses glutamate-induced inhibition of Akt-1 activity in neurons. Proc Natl Acad Sci USA 1999; 96:8745-50.
67. D'Onofrio M, Cuomo L, Battaglia G, Ngomba RT, Storto M, Kingston AE, et al. Neuroprotection mediated by glial group-II metabotropic glutamate receptors requires the activation of the MAP kinase and the phosphatidylinositol-3-kinase pathways. J Neurochem 2001; 78:435-45.
68. Ness JK, Wood TL. Insulin-like growth factor I, but not neurotrophin-3, sustains Akt activation and provides long-term protection of immature oligodendrocytes from glutamate-mediated apoptosis. Mol Cell Neurosci 2002; 20:476-88.
69. Mochizuki T, Asai A, Saito N, Tanaka S, Katagiri H, Asano T, et al. Akt protein kinase inhibits non-apoptotic programmed cell death induced by ceramide. J Biol Chem 2002; 277:2790-7.